Core Viewpoint - The stock of Zhaoke Ophthalmology-B (06622) has increased by over 5%, reflecting positive market sentiment following the expansion of its partnership agreement with AFT Pharmaceuticals Limited for the commercialization of BRIMOCHOL PF in Singapore [1] Group 1: Partnership Expansion - Zhaoke Ophthalmology-B has expanded its partnership with AFT Pharmaceuticals to commercialize BRIMOCHOL PF in Singapore [1] - The company has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen are now the seventh and eighth commercialization partners for BRIMOCHOL PF, indicating the company's commitment to global expansion [1] Group 2: Product Information - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia [1] - The product is a core asset acquired through a licensing agreement with Tenpoint Therapeutics, Ltd. [1]
港股异动 | 兆科眼科-B(06622)涨超5% 已扩大与AFT的伙伴协议 于新加坡商业化BRIMOCHOL? PF